National Toxicology Program

Aldrich (1994) Catalog Handbook of Fine Chemicals 1994-1995, Milwaukee, WI, Aldrich Chemical Co., Inc., p. 891

Anon. (1994a) Sales of melatonin grow in US. Gazeta Mercantil, (13 Sept. 1994), (20.418), 10

[Abstract 00319233. In: Dialog, 1996c]

Anon. (1994b) Dorland's Illustrated Medical Dictionary, 28th ed., Philadelphia, PA, W.B. Saunders Co., p. 1005

Anon. (1995a) Marker briefs: Melatonin. Chem. Mark. Rep., (16 Oct. 1995) 248(16), 16-17

Anon. (1995b) Advertisement: Melatonin. Chem. Mark. Rep., (13 Feb. 1995) 247(7), 20

Anon. (1995c) Alternative medicine approvals based on pilot efficacy trials urged by consultant. The Tan Sheet, (June 12, 1995) 3(Issue 24) [Abstract 00124331. In: Dialog, 1996b]

Anon. (1995d) Israel: Finetech to begin melatonin production in Mar 1996. Chimie Actualities, (25 Dec 1995) (572), B6 [Abstract 00387957. In: Dialog, 1996c]

Anon. (1995e) UK ends free sale of melatonin. World Pharm. News, (OTC News Supplement, Nov 1995), (21), 4 [Abstract 0535647. In: Dialog, 1996d]

Anon. (1995f) Herbal Roulette. Consumer Reports, [November 1995] 60(11), 698-705

Anon. (1996a) Melatonin. Chem. Mark. Rep., [11 March 1996] 249(11), 15

Anon. (1996b) Advertisements: US Air In Flight Magazine; Rodman's Drug Store advertising sheet; General Nutrition Centers (GNC) advertising leaflet

Anon. (1996c) European measures against melatonin. World Pharm. News, (OTC News Supplement, Feb 1996), (24), 3 [Abstract 0543562. In: Dialog, 1996d]

Blask, D.E., Pelletier, D.B., Hill, S.M., Lemus-Wilson, A., Grosso, D.S., Wilson, S.T. & Wise, M.E. (1991) Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J. Cancer Res. Clin. Oncol., 117, 526-532

Budavari, S., ed. (1989) The Merck Index, 11th ed., Rahway, NJ, Merck & Co., Inc., p. 912

Calbiochem (1995) Calbiochem Transduction Catalog & Technical Resource 1995, San Diego, CA, Calbiochem-Novabiochem International, p. 220

Cavallo, A. & Hassan, M. (1995) Stability of melatonin in aqueous solution. J. Pineal Res., 18(2), 90-92

Chemical Information Services, Inc. (1995) International Directory of Pharmaceutical Ingredients, 1995/96 edition, Dallas, TX, CIS Information Services, Inc., pp 605,71A,76A,124A

Cordell, G.A. (1978) Alkaloids. In: Grayson, M., ed., Kirk-Othmer Encyclopedia of Chemical Technology, 3rd ed., Vol. 1, New York, John Wiley & Sons, Inc., p. 906

CVM (1996) Melatonin Freedom of Information Summary, Rockville, MD, Center for Veterinary Medicine, Food and Drug Administration, Department of Health and Human Services, Internet address: http://www.cvm.fda.gov/

Dialog (1996) Dialog Information Service Databases: a) TSCA Inventory (file 52); b) F-D-C- Reports (file 187); c) Chemical Business NewsBase (file 319); d) Pharmaceutical News Index/Health News Daily (files 42/43), Palo Alto, CA, The DIALOG Information Retrieval Services, searched March, 1996

Dubocovich, M.L. (1988) Pharmacology and function of melatonin receptors. FASEB J., 2(12), 2765-2773

Engeland, W.C. (1995) Hormones. In: Howe-Grant, M., ed., Kirk-Othmer Encyclopedia of Chemical

Technology, 4th ed., Vol. 13, New York, John Wiley & Sons, Inc., pp. 357-370

Fluka (1995) Fluka Chemika-BioChemika 1995/96, Ronkonkoma, NY, Fluka Chemical Corp., p. 930

Garcia-Patterson, A., Puig-Domingo, M. & Webb, S.M. (1996) Mini Review. Thirty years of human pineal research: do we know its clinical relevance? J. Pineal Res., 20, 1-6

Garfinkel, D., Laudon, M., Nof, D. & Zisapel, N. (1995) Improvement of sleep quality in elderly people by controlled-release melatonin. The Lancet, 346, 541-543

Genzyme Corp. (1994) Material Safety Data Sheet: Melatonin, Cambridge, MA, Pharmaceuticals Division, Genzyme Corporation

Hashizume, T. Santo, H., Tsujisawa, H., Kosaka, K., Ozawa, T., Yamashita, M. & Kinae, N. (1991) Mutagenic activities of tryptophan metabolites before and after nitrite treatment. Food Chem. Toxicol. 29(12), 839-844

Hill, S.M., Spriggs, L.L., Simon, M.A., Muraoka, H. & Blask, D.E. (1992) The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett., 64, 249-256

Horn, A.S. (1981) Neuroregulators. In: Grayson, M., ed., Kirk-Othmer Encyclopedia of Chemical Technology, 3rd ed., Vol. 15, New York, John Wiley & Sons, Inc., pp. 771-772

Hunter, D., ed. (1995) ChemicalWeek 1996 Buyers' Guide, New York, Chemical Week Associates, p. 312

Kuney, J.H., ed. (1995) Chemcyclopedia 1995 - The Manual of Commercially Available Chemicals, Washington, DC, American Chemical Society, p. 432

Lissoni, P., Barni, S., Ardizzoia, A., Tancini, G., Conti, A. & Maestroni, G. (1994a) A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer, 73(3), 699-701

Lissoni, P., Barni, S., Tancini, G., Ardizzoia, A., Ricci, G., Aldeghi, R., Brivio, F., Tisi, E., Rovelli, F., Rescaldani, R., Quadro, G. & Maestroni, G. (1994b) A randomized study with subcutaneous low dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer, 69, 196-199

Lissoni, P., Barni, S., Tancini, G., Crispino, S., Paolorossi, F., Lucini, V., Mariani, M., Cattaneo, G., Esposti, D., Esposti, G. & Fraschini, F. (1987) Clinical study of melatonin in untreatable advanced cancer patients. Tumori, 73, 475-480

Lissoni, P., Brivio, F., Ardizzola, A., Tancini, G. & Barni, S. (1993) Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori, 79, 401-404

Malakhova, N.V. & Raushenbakh, M.O. (1986) Transplacental carcinogenic action of the serotonin derivative 5-methoxyindolyl-3-acetic acid. Bull. Exp. Biol. Med., 101(5), 670-672

Mauviard, F., Raynaud, F., Geoffriau, M., Claustrat, B. & Pevet, P. (1995) 5-Methoxypsoralen inhibits 6-hydroxylation of melatonin in the rat. Biol. Signals, 4(1), 32-41 [Abstract: CA 123,74831]

Neville, S. Arendt, J. & Ioannides, C. (1989) A study of the mutagenicity of melatonin and 6-hydroxymelatonin. J. Pineal Research, 6, 73-76

NLM (1996b) RTECS (Registry of Toxic Effects of Chemical Substances), Bethesda, MD, searched March, 1996 [Accession No. 21800]

Nordlund, J.J. & Lerner, A.B. (1977) The effects of melatonin on skin color and on the release of pituitary hormones. J. Clin. Endocrinol. Metab., 45(4), 768-774

Oaknin-Bendahan, S., Anis, Y., Nir, I. & Zisapel, N. (1995) Effects of long-term administration of melatonin and a putative antagonist on the ageing rat. NeuroReport, 6, 785-788

Olin, B.R., ed. (1996) American Drug Index, 40th Anniversary Edition, St. Louis, MO, Facts and Comparisons Co., p. 458

PDR (1996) Physicians' Desk Reference, 50th ed., Montvale, N.J., Medical Economics Company, p. 779

Pierpaoli, W. & Maestroni, G.J.M. (1987) Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-aging effects. Immunol. Lett., 16, 355-362

Pierpaoli, W. & Regelson, W. (1994) Pineal control of aging: effect of melatonin and pineal grafting on aging mice. Proc. Natl. Acad. Sci., 91, 787-791

Pierrefiche, G. Topall, G., Courboin, G., Henriet, I. & Laborit, H. (1993) Antioxidant activity of melatonin in mice. Res. Cammun. Chem. Path. Pharm., 80(2), 211-223

Praast, G., Bartsch, C., Bartsh, H., Mecke, D. & Lippert, T.H. (1995) Hepatic hydroxylation of melatonin in the rat is induced by phenobarbital and 7,12-dimethylbenz[a]anthracene - implications for cancer etiology. Experientia, 51, 349-355

Recio, J., Mediavilla, R.J., Cardinali, D.P. & Sanchez-Barcelo, E.J. (1994) Pharmacological profile and diurnal rhythmicity of 2-[125I]iodomelatonin binding sites in murine mammary tissue. J. Pineal Res., 16, 10-17

Reiter, R. (1991) Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine Reviews, 12(2), 151-180

Reiter, R. (1993) Interactions of the pineal hormone melatonin with oxygen-centered free radicals: a brief review. Brazilian J. Med. Biol. Res., 26(11), 1141-1155 [Abstract: AN 94184230]

Reiter, R.J., Barlow-Walden, L., Poeggeler, B., Heiden, S.M. & Clayton, R.J. (1996) Twenty-four hour urinary excretion of 6-hydroxymelatonin sulfate in Down syndrome subjects. J. Pineal Res., 20, 45-50

Reiter, R.J., Melchiorri, D., Sewerynek, E., Poeggeler, B., Barlow-Walden, L., Chuang, J., Ortiz, G.C. & Acuna-Castroviejo, D. (1995) A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res., 18, 1-11

Robinson, W.A., Dreiling, L., Gonzalez, R. & Balmer, C. (1995) Treatment of human metastatic malignant melanoma with high dose oral melatonin. In: Fraschini et al., eds., (1995) The pineal gland and its hormones, New York, Plenum Press, pp. 219-225

Sax, N.I. & Lewis, R.J., Sr., eds. (1989) Dangerous Properties of Industrial Materials, 7th ed., Vol. III, New York,

Van Nostrand Reinhold, p. 2175

Shellard, S.A., Whelan, R.D.H. & Hill, B.T. (1989) Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro. Br. J. Cancer, 60, 288-290

Sigma (1996) Biochemicals, Organic Compounds and Diagnostic Reagents, St. Louis, MO, Sigma Chemical Co., p.670

Singer, S.S., Hagedorn, J.E., Smith, D.M. & Williams, J.L. (1995) The enzymatic basis for the rat liver 6-hydroxy-melatonin sulfotransferase activity. J. Pineal Res., 18, 49-55

Spectrum (1995) Spectrum Bulk Chemicals & Intermediates, New Brunswick, N.J., Spectrum Chemical Mfg. Corp., p. S-73

Stieglitz, A., Spiegelhalter, F., Klante, G. & Heldmaier, G. (1995) Urinary 6-sulphatoxymelatonin excretion reflects pineal melatonin secretion in the Djungarian hamster (Phodopus sungorus). J. Pineal Res., 18, 69-76

STN (1996) STN International database file: CHEMCATS. Columbus, OH, Chemical Abstracts Service, searched March, 1996

Subramanian, A. & Kothari, L. (1991) Melatonin, a suppressor of spontaneous murine mammary tumors. J. Pineal Res., 10(3), 136-140

Sugden, D. (1983) Psychopharmacological effects of melatonin in mouse and rat. J. Pharmacol. Experim. Therap., 227(3), 587-591

Sze, S.F., Ng, T.B. & Liu, W.K. (1993) Antiproliferative effect of pineal indoles on cultured tumor cell lines. J. Pineal Res., 14, 27-33

Tamarkin, L., Cohen, M., Roselle, D., Reichert, C., Lippman, M. & Chabner, B. (1981) Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res., 41, 4432-4436

Tamarkin, L., Danforth, D., Lichter, A., DeMoss, E., Cohen, M., Chabner, B. & Lippman, M. (1982) Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science, 216, 1003-1005

Tan, D.-X., Pöeggeler, B., Reiter, R., Chen, L.-D., Chen S., Manchester, L.C. & Barlow-Walden, L.R. (1993) The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett., 70, 65-71

Tedesco, S.C., Morton, D.J. & Reiter, R.J. (1994) Hydroxyindole-O-methyltransferase activity in the pineal gland of the muskox (Ovibos moschatus). J. Pineal Res., 16, 121-126

Ubeda, A., Trillo, M.A., House, D.E. & Blackman, C.F. (1995a) Melatonin enhances junctional transfer in normal C3H/10T1/2 cells. Cancer Lett., 91, 241-245

Ubeda, A., Trillo, M.A., House, D.E. & Blackman, C.F. (1995b) A 50 Hz magnetic field blocks melatonin-induced enhancement of junctional transfer in normal C3H/10T1/2 cells. Carcinogenesis, 16(12), 2945-2949

US International Trade Commission (1991) Synthetic Organic Chemicals, US Production and Sales, 1989 (USITC Publication 2470), Washington, DC, US Government Printing Office, p. 6-13

US International Trade Commission (1993) Synthetic Organic Chemicals, US Production and Sales, 1991 (USITC Publication 2607), Washington, DC, US Government Printing Office, p. 6-12

US International Trade Commission (1994a) Synthetic Organic Chemicals, US Production and Sales, 1992 (USITC Publication 2720), Washington, DC, US Government Printing Office, p. 3-20

US International Trade Commission (1994b) Synthetic Organic Chemicals, US Production and Sales, 1989 (USITC Publication 2810), Washington, DC, US Government Printing Office, p. 3-183

Van, H., ed. (1995) OPD The Green Book Chemical Buyers Directory 1996, New York, NY, Schnell Publishing Co., p. 418

Voordouw, B.C.G., Euser, R., Verdonk, R.E.R., Alberda, B.T., De Jong, F.H., Drogendijk, A.C., Fauser, B.C.J.M. & Cohen, M. (1992) Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J. Clin. Endocrin. Metab., 74(1), 108-111

Weast, R.C. & Astle, M.J. (1985) Handbook of Data on Organic Compounds, Boca Raton, FL, CRC Press, Inc., p.

Webb, S.M. & Puig-Domingo, M. (1995) Role of melatonin in health and disease. Clin. Endocrinol., 42, 221-234

Williams, R.T. (1959) Detoxication Mechanisms, 2nd ed., London, Chapman Hall Ltd., p. 668-669